Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 5
2014 8
2015 11
2016 8
2017 14
2018 16
2019 11
2020 20
2021 22
2022 16
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35641302

110 results

Results by year

Filters applied: . Clear all
Page 1
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP. Oh WK, et al. Urol Oncol. 2018 Nov;36(11):500.e1-500.e9. doi: 10.1016/j.urolonc.2018.08.002. Epub 2018 Sep 7. Urol Oncol. 2018. PMID: 30201382 Free article.
Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S. Matsubara N, et al. Clin Genitourin Cancer. 2017 Dec;15(6):e1073-e1080. doi: 10.1016/j.clgc.2017.07.016. Epub 2017 Jul 26. Clin Genitourin Cancer. 2017. PMID: 28826931
Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.
Koshiro N, Nakajima K, Oyama M, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators. Koshiro N, et al. Int J Urol. 2022 Dec;29(12):1477-1487. doi: 10.1111/iju.15022. Epub 2022 Sep 7. Int J Urol. 2022. PMID: 36070138
110 results